Indian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations.

Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) had completed an inspection at its wholly owned subsidiary, Auroactive Pharma, located in Andhra Pradesh.

New York, July 17, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Active Pharmaceutical Ingredients (APIs) Market - Global Outlook ...

QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...

A review of 3,286 FDA warning letters has found that nearly one in three pharmaceutical CGMP warning letters contains ...

Ajinomoto Bio-Pharma Services is consolidating its various operations to streamline its offerings. (Ajinomoto Bio-Pharma) () Ajinomoto Bio-Pharma Services is taking full control of an API ...

Washington has spared India’s generics from its new drug tariffs. But the real exposure running through India’s pharmacy lies ...

India’s Torrent Pharma, which has been beefing up its international focused production capabilities, is buying an API operation from another Indian player. The Ahmedabad-based drugmaker today reported ...

New York, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pharmaceutical API Manufacturing Global Market Report 2021: COVID ...